Biblioteca
All documents
VICH/14/013 - Final - Implementation of VICH guidelines
VICH/14/013 - Final - Implementation of VICH guidelines
EWGs Posters exhibited during the Conference
Steering Committee
Anthelmintics EWG
Bioequivalence EWG
Biologicals EWG
Biologicals EWG Subgroups
Medicated Premixes EWG
MRK EWG
Pharmaceutical Combination Products EWG
Pharmacovigilance EWG
Quality EWG
Quality EWG Subgroups
Safety EWG
Session 1 - Welcome and Opening
Session 2 - Keynote Addresses
Why WOAH is a strong advocate of VICH? - M. Szabo
How is VICH responding to global needs in a new era? - M. Lucia
VICH achievements - H. Marion
Session 3 - VICH moving forwards
Restructuring (and future vision) - S. Iwamoto
VICH workplan - M. Churchill
The view of a VICH Forum member - Y. Kosenko
Session 4 - How VICH guidelines are developed, implemented and used
How VICH guidelines are developed, implemented and used - B. Boenisch
How VICH guidelines implement the 3Rs in safety studies - E. Werner
Challenges and perspectives in adopting VICH guidelines in VICH Forum countries/regions and how to overcome them - A. Ogutu
Session 5 - Scientific issues
Scientific topic 1: Safety of monoclonal antibodies - C. Stirling
Scientific topic 2: Pharmacovigilance and signal management - K. Schirmann
Scientific topic 3:– bioequivalence and dissolution testing - M. Martinez
Session 6 - New or revised VICH GLs
GL topic 1: anthelmintics - A. Phillippi-Taylor
GL topic 2: Good manufacturing practice for active pharmaceutical ingredients - M. Huynh
GL topic 3: pharmaceutical development - M. Huynh
Session 7 - Opportunities from international guidelines and regional collaborations
International collaborations - M. Bassi
GMP Inspections Reliance Programmes and Mutual Recognition Agreements - G. Verdier & P. Krauze
Regional collaboration and mutual reliance - I. Ravengai